Testosterone undecanoate

The US Food and Drug Administration (FDA) has approved

Oral testosterone undecanoate, is approved to treat men with hypogonadism resulting from specific medical conditions, such as genetic disorders like Klinefelter syndrome or tumors that have damaged the pituitary gland.

Trade name Jatenzo.

It is not be used to treat men with age-related hypogonadism, even if such patients have symptoms that appear to be related to low testosterone, as it’s benefits do not outweigh its risks.

Its effects on raising blood pressure can increase the risks of heart attack, stroke and cardiovascular death.

Results showed that 87% of men treated achieve an average testosterone level within the normal range.

Side effects include: headache, an increase in hematocrit level, a decrease in HDL cholesterol level, high blood pressure, nausea, and an increase in prostate specific antigen (PSA) level.

For patients taking the drug, the hematocrit, cholesterol, and PSA levels should be monitored regularly, and patients with benign prostate hyperplasia should be monitored for worsening of symptoms.

Patients’ risk for heart disease should be assessed and blood pressure be adequately controlled before prescribing the drug.

Leave a Reply

Your email address will not be published. Required fields are marked *